Astellas Pharma, Inc. (4503) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Astellas Pharma, Inc.

Chugai Pharmaceutical Co., Ltd.

Shionogi & Co., Ltd.

Otsuka Holdings Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Eisai Co., Ltd.

Kyowa Kirin Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is Astellas Pharma, Inc. ?

High Management Efficiency with a high ROE of 6.28%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.73

With a growth in Net Profit of 81.96%, the company declared Very Positive results in Jun 25

RAW MATERIAL COST(Y) Fallen by -1.98% (YoY)
OPERATING PROFIT(Q) Highest at JPY 157,307 MM
OPERATING PROFIT MARGIN(Q) Highest at 31.1 %

With ROE of 3.35%, it has a very attractive valuation with a 1.67 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 31.06%, its profits have risen by 293.2% ; the PEG ratio of the company is 0.2
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Astellas Pharma, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Astellas Pharma, Inc. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Astellas Pharma, Inc.

29.58%

481.49

25.28%

Japan Nikkei 225

28.54%

1.14

25.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.01%

EBIT Growth (5y)

-2.04%

EBIT to Interest (avg)

42.73

Debt to EBITDA (avg)

0.65

Net Debt to Equity (avg)

0.42

Sales to Capital Employed (avg)

0.74

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

261.05%

Pledged Shares

Institutional Holding

0.12%

ROCE (avg)

15.78%

ROE (avg)

6.28%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.67

EV to EBIT

12.39

EV to EBITDA

6.97

EV to Capital Employed

1.47

EV to Sales

1.66

PEG Ratio

0.17

Dividend Yield

0.04%

ROCE (Latest)

11.86%

ROE (Latest)

3.35%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -1.98% (YoY

OPERATING PROFIT(Q)

Highest at JPY 157,307 MM

OPERATING PROFIT MARGIN(Q)

Highest at 31.1 %

PRE-TAX PROFIT(Q)

At JPY 92,009 MM has Grown at 89.45%

NET PROFIT(Q)

At JPY 68,422 MM has Grown at 81.96%

-12What is not working for the Company

INTEREST(Q)

At JPY 5,898 MM has Grown at 50.96%

CASH AND EQV(HY)

Lowest at JPY 403,771 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.04%

Here's what is working for Astellas Pharma, Inc.

Operating Profit

Highest at JPY 157,307 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at 31.1 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY 92,009 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Pre-Tax Profit

At JPY 92,009 MM has Grown at 89.45%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 68,422 MM has Grown at 81.96%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

Raw Material Cost

Fallen by -1.98% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Astellas Pharma, Inc.

Interest

At JPY 5,898 MM has Grown at 50.96%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest

Highest at JPY 5,898 MM

in the last five periods and Increased by 50.96% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 403,771 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 3.04%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio